Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation

Transplant International

Volumn 25, Issue 10, 2012, Pages 1106-1116

  Matz, Mareen ^a   Lehnert, Martin ^a   Lorkowski, Christine ^a   Fabritius, Katharina ^a   Unterwalder, Nadine ^a   Doueiri, Salim ^a   Weber, Ulrike A ^a   Mashreghi, Mir Farzin ^b   Neumayer, Hans H ^a   Budde, Klemens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

B lymphocytes; everolimus; humoral rejection; MPA; sotrastaurin

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; EVEROLIMUS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; MYCOPHENOLIC ACID; SOTRASTAURIN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANTIGENS, CD80; ANTIGENS, CD86; APOPTOSIS; B-LYMPHOCYTES; CELL MEMBRANE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GRAFT REJECTION; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; MYCOPHENOLIC ACID; PYRROLES; QUINAZOLINES; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84866277124     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01537.x     Document Type: Article

References (56)

1. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132.
2. Kasiske BL, Zeier MG, Craig JC, et al,. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl. 3): S1.
3. Stegall MD, Gloor JM,. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15: 8.
4. Stegall MD, Raghavaiah S, Gloor JM,. The (re)emergence of B cells in organ transplantation. Curr Opin Organ Transplant 2010; 15: 451.
5. Bartel G, Schwaiger E, Bohmig GA,. Prevention and treatment of alloantibody-mediated kidney transplant rejection. Transpl Int 2011; 24: 1142.
6. Jordan SC, Kahwaji J, Toyoda M, Vo A,. B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr Opin Organ Transplant 2011; 16: 416.
7. Waiser J, Budde K, Schutz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant 2012; 27: 1246.
8. Kozlowski T, Andreoni K,. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Ann Transplant 2011; 16: 19.
9. Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK,. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother 2011; 12: 579.
10. Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011; 11: 1218.
11. Woodle ES, Walsh RC, Alloway RR, Girnita A, Brailey P,. Proteasome inhibitor therapy for antibody-mediated rejection. Pediatr Transplant 2011; 15: 548.
12. Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486.
13. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
14. Struijk GH, Minnee RC, Koch SD, et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney Int 2010; 78: 934.
15. Willcocks LC, Chaudhry AN, Smith JC, et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. Am J Transplant 2007; 7: 2006.
16. Heine G, Niesner U, Chang HD, et al. 1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells. Eur J Immunol 2008; 38: 2210.
17. Heidt S, Roelen DL, Eijsink C, Eikmans M, Claas FH, Mulder A,. Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production. Clin Exp Immunol 2009; 158: 99.
18. Ruprecht CR, Lanzavecchia A,. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006; 36: 810.
19. Heidt S, Roelen DL, Eijsink C, et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol 2010; 159: 199.
20. Cai J, Terasaki PI,. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol 2005; 66: 334.
21. Terasaki PI, Cai J,. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005; 17: 541.
22. Seveso M, Bosio E, Ancona E, Cozzi E,. De novo anti-HLA antibody responses after renal transplantation: detection and clinical impact. Contrib Nephrol 2009; 162: 87.
23. Rowshani AT, Bemelman FJ, Lardy NM, Ten Berge IJ,. Humoral immunity in renal transplantation: clinical significance and therapeutic approach. Clin Transplant 2008; 22: 689.
24. Wagner J, von Matt P, Sedrani R, et al. Discovery of 3-(1H-indol-3-yl)-4- [2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5 -dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. J Med Chem 2009; 52: 6193.
25. Evenou JP, Wagner J, Zenke G, et al. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmacol Exp Ther 2009; 330: 792.
26. Matz M, Weber U, Mashreghi MF, et al. Effects of the new immunosuppressive agent AEB071 on human immune cells. Nephrol Dial Transplant 2010; 25: 2159.
27. Friman S, Arns W, Nashan B, et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant 2011; 11: 1444.
28. Budde K, Sommerer C, Becker T, et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am J Transplant 2010; 10: 571.
29. Matz M, Naik M, Mashreghi MF, Glander P, Neumayer HH, Budde K,. Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation. Expert Opin Drug Metab Toxicol 2011; 7: 103.
30. Brick-Ghannam C, Ericson ML, Schelle I, Charron D,. Differential regulation of mRNAs encoding protein kinase C isoenzymes in activated human B cells. Hum Immunol 1994; 41): 216.
31. Mischak H, Kolch W, Goodnight J, et al. Expression of protein kinase C genes in hemopoietic cells is cell-type- and B cell-differentiation stage specific. J Immunol 1991; 147: 3981.
32. Su TT, Guo B, Kawakami Y, et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002; 3: 780.
33. Saijo K, Mecklenbrauker I, Santana A, Leitger M, Schmedt C, Tarakhovsky A,. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J Exp Med 2002; 195: 1647.
34. Li ZW, Omori SA, Labuda T, Karin M, Rickert RC,. IKK beta is required for peripheral B cell survival and proliferation. J Immunol 2003; 170: 4630.
35. Guo B, Su TT, Rawlings DJ,. Protein kinase C family functions in B-cell activation. Curr Opin Immunol 2004; 16: 367.
36. Antony P, Petro JB, Carlesso G, Shinners NP, Lowe J, Khan WN,. B cell receptor directs the activation of NFAT and NF-kappaB via distinct molecular mechanisms. Exp Cell Res 2003; 291: 11.
37. Choi MS, Brines RD, Holman MJ, Klaus GG,. Induction of NF-AT in normal B lymphocytes by anti-immunoglobulin or CD40 ligand in conjunction with IL-4. Immunity 1994; 1: 179.
38. Ozcan E, Rauter I, Garibyan L, Dillon SR, Geha RS,. Toll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand interactor, and CD40 synergize in causing B-cell activation. J Allergy Clin Immunol 2011; 128: 601.
39. Matsumoto M, Fujii Y, Baba A, Hikida M, Kurosaki T, Baba Y,. The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. Immunity 2011; 34: 703.
40. Naylor TL, Tang H, Ratsch BA, et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011; 71: 2643.
41. Carey GB, Semenova E, Qi X, Keegan AD,. IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contribution of the PI-3 kinase/AKT pathway. Cell Res 2007; 17: 942.
42. Rothstein TL, Foote LC, Schneider TJ, et al. Inducible resistance to Fas-mediated apoptosis in primary B lymphocytes. Adv Exp Med Biol 1996; 406: 177.
43. Foote LC, Howard RG, Marshak-Rothstein A, Rothstein TL,. IL-4 induces Fas resistance in B cells. J Immunol 1996; 157: 2749.
44. Acosta Rodriguez EV, Zuniga E, Montes CL, Gruppi A,. Interleukin-4 biases differentiation of B cells from Trypanosoma cruzi-infected mice and restrains their fratricide: role of Fas ligand down-regulation and MHC class II-transactivator up-regulation. J Leukoc Biol 2003; 73: 127.
45. Nakanishi K, Matsui K, Kashiwamura S, et al. IL-4 and anti-CD40 protect against Fas-mediated B cell apoptosis and induce B cell growth and differentiation. Int Immunol 1996; 8: 791.
46. Sun Q, Liu ZH, Cheng Z, et al. Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil. Kidney Int 2007; 71: 24.
47. Sun Q, Liu ZH, Yin G, et al. Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients. Nephrol Dial Transplant 2006; 21: 510.
48. Ji SM, Liu ZH, Chen JS, Sha GZ, Ji DX, Li LS,. Rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil for C4d-positive acute humoral renal allograft rejection. Transplant Proc 2006; 38: 3459.
49. Venetz JP, Pascual M,. New treatments for acute humoral rejection of kidney allografts. Expert Opin Investig Drugs 2007; 16: 625.
50. Heidt S, Roelen DL, Eijsink C, van Kooten C, Claas FH, Mulder A,. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation 2008; 86: 1292.
51. Van Rijen MM, Metselaar HJ, Hommes M, Ijzermans JN, Tilanus HW, Kwekkeboom J,. Mycophenolic acid is a potent inhibitor of the expression of tumour necrosis factor- and tumour necrosis factor-receptor superfamily costimulatory molecules. Immunology 2003; 109: 109.
52. Vogelbacher R, Meister S, Guckel E, et al. Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. Nephrol Dial Transplant 2010; 25: 3764.
53. Pescovitz MD, Book BK, Henson S, et al. The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin. Am J Transplant 2003; 3: 497.
54. Cordero E, Perez-Ordonez A, Aydillo TA, et al. Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients. Am J Transplant 2011; 11: 2205.
55. Koch M, Mengel M, Poehnert D, Nashan B,. Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients. Transplantation 2007; 83: 498.
56. Bohler T, Waiser J, Lichter S, et al., Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients. Cytokine 2008; 42: 306.